

Cerebral perfusion in untreated, controlled, and uncontrolled hypertension

Isabel N Christie¹, Rowan Windsor¹, Henk JMM Mutsaerts², Therese Tillin³, Carole H Sudre³, Alun D Hughes⁴, Xavier Golay⁵, Alexander V Gourine^{1,CA} & Patrick S Hosford^{1,CA}

¹*Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology and Pharmacology, University College London, London, UK;*

²*Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.*

³*MRC Unit for Lifelong Health & Ageing, Population Science & Experimental Medicine, Faculty of Population Health Sciences, University College London, London, UK;*

⁴*Institute of Cardiovascular Science, Population Science & Experimental Medicine, Faculty of Population Health Sciences, University College London, London, UK;*

⁵*Queen Square Institute of Neurology, University College London, London, UK.*

Running title: Cerebral perfusion in hypertension

^{CA}Corresponding authors:

Alexander V Gourine, PhD; a.gourine@ucl.ac.uk

Patrick S Hosford, PhD; patrick.hosford@riken.jp

1 **Abstract**

2
3
4 This study evaluated the association between systemic arterial blood pressure and cerebral perfusion in
5 740 participants of the UK's largest tri-ethnic study with measurements of cerebral blood flow (CBF)
6 performed using arterial spin labelling MRI. A significant negative correlation between blood pressure, age
7 and CBF was observed across the patient cohort. Lowest CBF values were recorded in the group of patients
8 with hypertension that were prescribed with anti-hypertensive drugs, but uncontrolled on medication. These
9 findings confirm that hypertension is associated with reduced cerebral perfusion and highlight the
10 importance of blood pressure control for the benefit of maintaining brain blood flow.
11
12
13
14
15

16 **Key Words** blood, brain, hypertension, MRI, perfusion,
17
18

19 **Main text**

20
21
22
23 Hypertension affects 1.5 billion people worldwide and its prevalence increases as the global population
24 ages. Hypertension is now considered one of the leading causes of age-related cognitive impairment and
25 is strongly associated with reduced cerebral blood flow (CBF)^{1,2}. There is significant evidence that reduced
26 brain perfusion, sustained over many years, leads to progressive cognitive decline, development of
27 dementia and neurodegenerative disease, such as Alzheimer's disease¹. The effect of anti-hypertensive
28 drugs on CBF in hypertensive patients remains unclear. Different studies reported decreases, increases or
29 no changes in CBF in response to anti-hypertensive medications^{3,4}. Two recent systematic reviews
30 highlighted that many of these studies were small, underpowered, and showed evidence of a significant
31 (moderate-to-high) risk of bias^{3,4}.
32
33
34
35
36
37

38
39 Here we evaluated the association between systemic arterial blood pressure and cerebral perfusion in a
40 cohort of patients recruited in the Southall and Brent Revisited (SABRE) study, the UK's largest tri-ethnic
41 longitudinal study involving 740 subjects⁵ with measurements of cerebral perfusion performed using arterial
42 spin labelling perfusion MRI and quantified using a single compartment model without partial volume
43 correction⁶. The study cohort included white European (41.7%), first South Asian (33.7%) and African
44 Caribbean (23.5%) participants (327 females, 413 males; mean (SD) age 71(7) years). Office blood
45 pressure measurements were obtained on the same day when cerebral perfusion was assessed. The
46 participants' data were excluded from the analysis if records were incomplete and/or recorded grey matter
47 perfusion values were lower than 20 ml/100 g/min. Data obtained in 690 participants were included in the
48 final analysis. Recorded values of systolic blood pressure and patient's history of hypertension were used
49 to stratify the study cohort into 4 groups: i) individuals with normal blood pressure [243 participants; mean
50 systolic blood pressure (SD) 117(9) mmHg; mean (SD) age 70(7) years]; ii) patients with untreated
51 hypertension, not receiving any anti-hypertensive drugs [250 participants; systolic mean 145(12) mmHg;
52
53
54
55
56
57
58
59
60

1 age 72(7) years]; iii) patients with hypertension, controlled on medication with a systolic blood pressure of
2 <130 mmHg [94 participants; systolic mean 117(9) mmHg; age 71(6) years]; and iv) patients with
3 hypertension, prescribed with anti-hypertensive drugs, but uncontrolled on medication with a systolic blood
4 pressure of \geq 130 mmHg [103 participants; systolic mean 144(12) mmHg; age 72(6) years].
5
6
7

8 Accounting for the covariants of age, body mass index (BMI) and sex, a significant negative correlation
9 between systolic arterial blood pressure and cerebral perfusion in both grey (p=0.01, R²= 0.05) and white
10 matter (p=0.001, R²= 0.06) was observed across the whole patient cohort (Figure 1A-C). Subsequent group-
11 wise analysis revealed a difference between participants with normal blood pressure and both unmedicated
12 participants with hypertension (p=0.02, grey matter; p=0.002 white matter) and patients with high blood
13 pressure, who were prescribed but uncontrolled on medication (p=0.004, grey matter; p=0.007; white
14 matter). The mean CBF (\pm SD) in the participants with normal blood pressure was 39 \pm 7 mL/100 g/min in
15 the grey matter and 14.5 \pm 4 mL/100 g/min in the white matter (n=243). The lowest values of CBF were
16 recorded in the group of patients with high blood pressure that were uncontrolled on medication 36 \pm 6
17 mL/100 g/min in the grey matter and 13 \pm 3 mL/100 g/min¹ in the white matter (n=103; Figure 1D,E)
18
19
20
21
22
23
24
25

26 These data confirm that high systemic arterial blood pressure is associated with reduced cerebral perfusion.
27 The data do not support the results of a previous study that reported no significant CBF differences between
28 normotensive subjects and individuals with untreated hypertension⁷. In a recent longitudinal study
29 undertaken in older (mean age 77 years) individuals with hypertension, the use of anti-hypertensive
30 medication was found to be associated with lower grey matter CBF⁸. In contrast, another recent study
31 involving participants aged 50 years or older (mean age 67.5 years) showed that intensive anti-hypertensive
32 treatment (to achieve systolic blood pressure target of <120 mmHg) was associated with increased, rather
33 than decreased, perfusion in the grey and white matter⁹. Our analysis suggests that anti-hypertensive
34 treatment has no deleterious effect on cerebral perfusion if systemic arterial blood pressure is controlled on
35 medication and supports the conclusions of the meta-analysis conducted by Van Rijssel and colleagues⁴.
36 These findings highlight the importance of blood pressure control not only for the purpose of reducing the
37 risk of stroke, cardiovascular disease, heart and renal failure, but also for the benefit of maintaining
38 adequate cerebral blood flow and protecting the brain from harmful effects of chronically reduced perfusion.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Acknowledgements: This work was supported by The Wellcome Trust (AVG; refs: 200893 and 223057) and
2 the British Heart Foundation (AVG; ref: RG/19/5/34463). AVG was supported by a Wellcome Senior
3 Research Fellowship (ref: 200893). HM is supported by the Dutch Heart Foundation (03-004-2020-T049),
4 by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and
5 innovation programme (ASPIRE E!113701), provided by the Netherlands Enterprise Agency (RvO), and by
6 the EU Joint Program for Neurodegenerative Disease Research, provided by the Netherlands Organisation
7 for health Research and Development and Alzheimer Nederland (DEBBIE JPND2020-568-106).
8
9
10
11
12

13 Competing interests: AVG is a founder and Chief Scientific Officer for Afferent Medical Solutions. XG is a
14 founder and shareholder of Gold Standard Phantoms, a company producing ASL perfusion phantoms. The
15 other authors declare no competing interests.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Iadecola, C. & Gottesman, R.F. Neurovascular and cognitive dysfunction in hypertension. *Circ. Res.* **124**, 1025-1044 (2019).
2. Ungvari, Z. *et al.* Hypertension-induced cognitive impairment: from pathophysiology to public health. *Nat. Rev. Nephrol.* **17**, 639-654 (2021).
3. Webb, A.J.S. Effects of vasodilating medications on cerebral haemodynamics in health and disease: systematic review and meta-analysis. *J. Hypertens.* **37**, 1119-1125 (2019).
4. van Rijssel, A.E. *et al.* Effect of antihypertensive treatment on cerebral blood flow in older adults: a systematic review and meta-analysis. *Hypertension* **79**, 1067-1078 (2022).
5. Leeuwis, A.E. *et al.* Cerebral blood flow and cognitive functioning in a community-based, multi-ethnic cohort: The SABRE study. *Front Aging Neurosci.* **10**, 279 (2018).
6. Mutsaerts, H.J.M.M. *et al.* ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies. *Neuroimage* **219**, 117031 (2020).
7. Warnert, E.A. *et al.* Is high blood pressure self-protection for the brain? *Circ. Res.* **119**, e140-e151 (2016).
8. van Dalen, J.W. *et al.* Longitudinal relation between blood pressure, antihypertensive use and cerebral blood flow, using arterial spin labelling MRI. *J. Cereb. Blood Flow Metab* **41**, 1756-1766 (2021).
9. Dolui, S. *et al.* Association of intensive vs standard blood pressure control with cerebral blood flow: Secondary analysis of the SPRINT MIND randomized clinical trial. *JAMA Neurol.* **79**, 380-389 (2022).

1 **Figure legend**

2
3
4 **Figure 1|** Cerebral perfusion in untreated, controlled, and uncontrolled hypertension. Summary plots
5 illustrating the relationships between grey (A) and white (B) matter perfusion and systolic arterial blood
6 pressure (SBP). Linear fit regression line is shown \pm 95% CI. Participant's medication status groups are
7 indicated: (i) individuals with normal blood pressure, not taking any anti-hypertensive medication with a SBP
8 of <130 mmHg; (ii) patients with untreated hypertension, not taking any anti-hypertensive medication with
9 a SBP ≥ 130 mmHg; (iii) patients with controlled hypertension, taking anti-hypertensive medication with a
10 SBP of <130 mmHg; and (iv) patients with hypertension prescribed with anti-hypertensive drugs, but
11 uncontrolled on medication with a SBP of ≥ 130 mmHg. (C) The relationship between age and cerebral
12 perfusion measured by ASL. Linear fit regression line is shown \pm 95% CI. (D,E) summary data illustrating
13 the differences in grey and white matter perfusion between 4 groups of patients. Groups were compared
14 using ANCOVA with age, BMI, and sex as covariants and Tukey's multiple comparison correction for post-
15 hoc analysis. Violin plots show arithmetic mean (central point) \pm SD with the outline illustrating kernel
16 probability density. Indicated P values were obtained in comparison to the normotensive group data.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1| Cerebral perfusion in untreated, controlled, and uncontrolled hypertension. Summary plots illustrating the relationships between grey (A) and white (B) matter perfusion and systolic arterial blood pressure (SBP). Linear fit regression line is shown \pm 95% CI. Participant's medication status groups are indicated: (i) individuals with normal blood pressure, not taking any anti-hypertensive medication with a SBP of <130 mmHg; (ii) patients with untreated hypertension, not taking any anti-hypertensive medication with a SBP >130 mmHg; (iii) patients with controlled hypertension, taking anti-hypertensive medication with a SBP of <130 mmHg; and (iv) patients with hypertension prescribed with anti-hypertensive drugs, but uncontrolled on medication with a SBP of >130mmHg. (C) The relationship between age and cerebral perfusion measured by ASL. Linear fit regression line is shown \pm 95% CI. (D,E) summary data illustrating the differences in grey and white matter perfusion between 4 groups of patients. Groups were compared using ANCOVA with age, BMI, and sex as covariants and Tukey's multiple comparison correction for post-hoc analysis. Violin plots show arithmetic mean (central point) \pm SD with the outline illustrating kernel probability density. Indicated P values were obtained in comparison to the normotensive group data.